Carvedilol Tablet, Film Coated
Product Images NDC 71335-1813

6 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Carvedilol (NDC 71335-1813). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A line graph depicting percent mortality over months (0 to 21) comparing Carvedilol and placebo groups. The Carvedilol line shows consistently lower mortality rates than placebo, with a p-value of 0.0014 indicating statistical significance.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A forest plot depicting hazard ratios for various patient subgroups including men, women, age groups, racial groups, diabetic status, ischemic status, heart rate, systolic blood pressure, and spironolactone use, compared to an overall patient population. The plot shows points and confidence intervals for each subgroup across a horizontal axis labeled 'Hazard ratio' ranging from 0.0 to 2.0.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A line graph comparing the percentage mortality over 24 months between patients treated with Carvedilol and a placebo. The x-axis represents time in months, and the y-axis shows percentage mortality. The graph includes a p-value of 0.03, indicating statistical comparison between the two groups.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A figure presenting hazard ratios with confidence intervals for various patient subgroups. The plotted subgroups include age ranges, gender, randomized treatment days, prior use of IV/oral beta-blockers, Killip class, presence of thrombolytic therapy, PTCA for myocardial infarction, heart failure status, diuretic use during myocardial infarction, angina, hypertension, diabetes, heart rate categories, and systolic blood pressure categories. The chart compares these variables regarding an outcome, with hazard ratios along a horizontal axis from 0.4 to 1.3.*
FDA Label Image

Label (Lbl713351813)

Label (Lbl713351813)
Label for Carvedilol 12.5 mg film-coated tablet packaged by Bryant Ranch Prepack in Burbank, CA. The label compares this product to Coreg 12.5 mg tablets by Beximco Pharmaceuticals Ltd, indicates a package count of 30 tablets, and shows storage instructions at 20-25°C (68-77°F). The label also includes a barcode and NDC 71335-1813.*
FDA Label Image

Structural Formula (Structure)

Structural Formula (Structure)
Chemical structure diagram of Carvedilol, showing the molecular arrangement including aromatic rings, hydroxyl groups, and ether linkages.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.